摘要
目的探讨放射性125I粒子植入治疗对晚期不能切除的分化型甲状腺癌疗效及生活质量的影响。方法回顾性分析晚期不能切除的分化型甲状腺癌8例11个病灶,在B型超声或CT引导下植入125I粒子,活度0.5～0.7 mCi,术后验证D90(90%靶体积接受的剂量)为74.6～138.8 Gy,观察患者局部控制率、生存率、生活质量的改善情况及不良反应。结果随访12-93月(中位随访时间22.5月),CR 2例,PR 5例,SD 1例,PD 3例,中位局部控制时间为20月,1年、2年局部控制率分别为81.8%、36.4%。中位生存期为22.5月,1年、2年生存率为100.0%、37.5%。植入后3月中位KPS评分较植入前提高20分(P=0.01),3例出现Ⅰ级放射性损伤,未见其他粒子相关不良反应。结论125I粒子植入治疗晚期不能切除的分化型甲状腺癌安全有效,并可改善患者生活质量。
Objective To assess the efficacy of brachytherapy with ^125I seeds implantation for treatment of advanced unresectable differentiated thyroid carcinoma. Methods Eight patients （11 lesions） with advanced unresectable differentiated thyroid cancer underwent ^125I seeds implantation under B-ultrasound and CT guidance. The activity of ^125I seeds ranged from 0.5 to 0.7 mCi and the D90 of the tumor ranged from 74.6 to 138.8 Gy shown by post plan. The local control rate,survival rate,quality of life and adverse reactions were observed after implantation. Results The patients were followed up for 12 - 93 months with a median of 22.5 months. The results showed CR in 2 cases,PR in 5 cases,SD in 1 case and PD in 3 cases. The median time of local control was 20 months,and the 1-,2-year local control rates were 81.8% and 36.4% ,respectively. The 1-,2-year survival rates were 100.0% and 37.5% with a median time of 22.5 months. The median KPS score on 3 months after implantation increased 20 points than pre-implantation （ P = 0. 01 ）. Grade I radiation injury was found in 3 patients ,while no other 125I seeds-related adverse reactions were observed. Conclusion ^125I seeds interstitial implantation for advanced unresectable differentiated thyroid carcinoma is effective and safe,it also can improve the quality of life for patients.
出处
《实用肿瘤杂志》
CAS
2013年第2期193-196,共4页
Journal of Practical Oncology
关键词
甲状腺肿瘤
放射疗法
碘放射性同位素
治疗应用
碘放射性同位素
投药和剂量
生活质量
存活率
随访研究
thyroid neoplasms/radiotherapy
iodine radioisotopes/therapeutic use
iodine radioisotopes/administration ＆ dosage
quality of life
survival rate
follow-up studies
